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Breast cancer is the most common malignancy in women in North
America and northwestern Europe, with 33 000 new cases diag-
nosed and 14 000 deaths per year in the UK alone. In contrast, the
risk of breast cancer in Asia is only one-quarter of that in the West
(Messina et al, 1994; Peterson, 1995). This discrepancy has been
associated with differences in dietary habits. For example Asians
consume 20–50 times more soy per capita than Westerners (Shao
et al, 1998). Soy contains the isoflavones genistein and daidzein in
the form of their glycosidic conjugates (Peterson, 1995), and it has
been proposed that these isoflavones can prevent breast cancer
(Fotsis et al, 1993; Lamartiniere et al, 1995). Genistein at 10–
100 µ M inhibits the growth and survival of cancer cells derived
from the human breast (Zava and Duwe, 1997; Fioravanti et al,
1998; Bail et al, 1998; Hsieh et al, 1998). Growth-inhibitory
effects of genistein may be linked to its ability to elicit apoptosis
(Shao et al, 1998; Li et al, 1999; Balabhadrapathruni et al, 2000).
Paradoxically, genistein at 1–5 µ M has been shown to stimulate,
rather than attenuate, the growth of MCF-7 breast cancer cells
(Zava and Duwe, 1997; Fioravanto et al, 1998; Bail et al, 1998;
Hsieh et al, 1998). The mechanisms by which genistein modulates
growth and survival of breast cells and prevents breast cancer are
not fully understood. As genistein is a phytoestrogen, it may influ-
ence cell growth via inhibitory or stimulatory interaction with the
oestrogen receptor (Kuiper et al, 1997; 1998). It also possesses
antioxidant properties (Barnes and Peterson, 1995) and inhibits
DNA topoisomerase II activity (Barnes and Peterson, 1995;
Kaufmann, 1998), angiogenesis (Fotsis et al, 1993) and cell cycle
regulatory molecules (Shao et al, 1998; Choi et al, 1998), all
processes that may be invoked in its chemopreventive activity.
Genistein can interfere with cellular signalling by inhibiting 
the activities of several kinases (Barnes and Peterson, 1995;
Kaufmann, 1998), prominent among them epidermal growth
factor receptor protein tyrosine kinase (Akiyama et al, 1987). One
such pathway involves phosphorylation of mitogen-activated
protein kinases (MAPK), such as the ERKs, and culminates in
the activation of the transcription factor AP-1 (Karin, 1996; Leppa
and Bohnmann, 1999). AP-1 comprises dimers of the c-fos and
c-jun protein families (Angel and Karin, 1991; Karin, 1996),
and binds to the 12-O-tetradecanoylphorbol-13-acetate (TPA) re-
sponse element (TRE), a specific target site in the promoters of
several genes germane to growth and survival (Smith et al, 1997).
Genistein has been shown to attenuate the transcription of c-fos
mRNA in breast cancer cells (Schultze-Mosgau et al, 1998) and
inhibit both UVB-and TPA-induced c-fos and c-jun expression in
mouse skin (Wei et al, 1996; Wang et al, 1998). 
Almost all of the published studies on the effect of genistein on
breast cell growth and cellular signalling mechanisms have
focussed on a small number of cell types, in particular on MCF-7
cells. The study described here was designed to explore generic
features pertinent to the modulation of breast cell growth by genis-
tein using a panel of 6 cell types, and to highlight differences
between cell lines in their response to genistein. To that end effects
of genistein on the following human breast cell types were
compared: MCF-7, ZR-75.1, T47-D, MDA-MB 468 and MDA-
MB 231 cells, all of which are malignant, and HBL 100 cells,
which are immortalized but not malignant. Furthermore we wished
to relate differences between cells in their growth response to
genistein with their susceptibility towards genistein-induced
biochemical changes that may contribute to cell growth inhibition,
such as changes in cell cycle regulation, AP-1 activity and levels of
c-fos and c-jun proteins. 
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Summary Genistein is thought to contribute to the putative breast cancer preventive activity of soya. The mechanisms by which it arrests the
growth of breast cells are incompletely understood. In order to explore generic features of the modulation of human breast cell growth by
genistein, its effects on cell lines MCF-7, ZR-75.1, T47-D, MDA-MB 468, MDA-MB 231 and HBL 100 were compared. Genistein at 1 µ M
stimulated growth only in MCF-7 cells. At 10 µ M it arrested the growth of all 6 cell types, however that of T47-D and HBL 100 cells only in
medium with reduced (2%) fetal calf serum. Genistein induced apoptosis in only MDA-MB 468 cells. It arrested cells in the G2 stage of the cell
cycle in all cell lines except ZR-75.1. Cells differed in their susceptibility towards inhibition by genistein of phorbol ester-induced proto-
oncogene c-fos levels, transcription factor activator protein-1 (AP-1) activity and extracellular signal-regulated kinase (ERK) activity. Genistein
augmented anisomycin-induced levels of proto-oncogene c-jun in ZR 75.1 and MCF-7 cells. The results suggest that induction of apoptosis,
G2 cell cycle arrest and inhibition of c-fos expression, AP-1 transactivation and ERK phosphorylation may contribute to the growth-inhibitory
effect of genistein in some breast cell types, but none of these effects of genistein constitutes a generic mode of growth-arresting action. 
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MATERIAL AND METHODS 
Cell lines and chemicals 
HBL 100, MCF-7, ZR-75.1, T47-D, MDA-MB 468 and MDA-MB
231 cells were originally obtained from the American Type
Culture Collection (Manassas, VA, USA). Media were purchased
from Gibco Life Technologies (Paisley, UK). Genistein, 12-O-
tetradecanoylphorbol-13-acetate (TPA) and anisomycin were
purchased from Sigma-Aldrich Company Ltd. (Poole, UK).
Genistein and TPA were dissolved in dimethylsulphoxide
(DMSO), aliquoted and frozen until use. Control incubates
contained DMSO only, and at the concentrations used (at or below
0.01%) DMSO did not interfere with growth. FuGene transfection
reagent was purchased from Boehringer Mannheim (Lewes, UK).
The antibodies for phosphorylated ERK (pERK), c-fos and c-jun
were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The annexin V reagent was obtained from Bender
MedSystems (Vienna, Austria). The antibody for poly (ADP-
ribose)-polymerase (PARP) and N-acetyl-Asp-Glu-Val-Asp 7-
amido-4-trifluoromethyl coumarin (DEVD.afc) enzyme substrate
(used for the determination of apoptosis) was kindly provided
by Dr M. MacFarlane (MRC Toxicology Unit, University of
Leicester), and glutathione-S-transferase (GST)-c-jun protein (for
measurement of c-jun N-terminal kinase [JNK] activity) was a gift
from Dr M. Dickens (Department of Biochemistry, University of
Leicester, UK). 
Cell growth studies 
Cells were routinely passaged in the following media, all supple-
mented with 10% fetal calf serum (FCS): RPMI-1640 and 2 mM
glutamax (MDA-MB 468 and MCF-7), DMEM/F12 (Ham) 1:1
containing 2 mM glutamax, 15 mM HEPES (ZR-75.1), DMEM
containing 1 g l–1 glucose, 2 mM glutamax, 110 mg l–1 sodium
pyruvate (HBL 100, T47-D and MDA-MB 231). All cell lines
tested negative for mycoplasma infection. For studies of the effect
of genistein on growth, cells seeded at 2 × 104 per well (17.5 mm)
were grown in media supplemented with FCS (10% or 2%). After
a 48-hour attachment period, cells were incubated with genistein
(1 µ M or 10 µ M) for 96 h and subsequently counted with a
Coulter Counter ZM (Beckman Coulter, Luton, UK). 
Flow-cytometric analysis 
For cell cycle investigations, cells (1 or 2 × 106 per 35 mm well)
were incubated with genistein (10 µ M) for 96 h after a 24-hour
attachment period in medium with 2% FCS. Cells were harvested
by trypsinization, washed with PBS, then pellets were resuspended
in ethanol (70%, 2 ml) and incubated for 3 h at 4˚C. RNase
(0.1 mg) and propidium iodide (5 µ g) were added, and cells were
kept for 24 h (4˚C) (Rickwood and Hames, 1990). Flow cytometric
analysis was performed using a FACScan flow cytometer (Becton
Dickinson, San Jose, CA, USA) with Cell Quest software. 
Measurement of apoptosis 
For assessment of apoptosis, cells (1 or 2 × 106 per 35 mm well)
were incubated with genistein (10 µ M) for 96 h after a 24-hour
attachment period in medium with 10% FCS. Cells obtained by
trypsinization were combined with those that had spontaneously
detached during the incubation. Apoptosis was assessed in 3 ways.
To determine phosphatidylserine externalization by annexin V
staining, cells were pelleted and suspended in annexin buffer
(1 ml; 10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2). Annexin V was added to cells (final
concentration 100 ng ml–1), and cells were incubated for 8 min at
room temperature, after which propidium iodide (1.5 µ g) was
added, and cells were analysed by flow cytometry. 
To measure PARP cleavage (Germain et al, 1999), the cell pellet
was washed with PBS, snap-frozen in liquid nitrogen and thawed
at 37˚C 3 times in succession. The resulting pellet was resus-
pended in sample buffer. Samples were sonicated and subjected to
SDS-PAGE as described (Sambrook et al, 1989). Membranes were
blocked in 5% non-fat milk in Tris-buffered saline with Tween-20
(TBS-T) for 1 h at room temperature and incubated for 1 h with a
PARP-specific antibody (1:10 000 dilution). For detection the
enhanced chemiluminescence (ECL) detection system (Amersham
Life Science Ltd, Little Chalfont, UK) was used. 
To measure caspase-3 activity (MacFarlane et al, 1997), cells
were harvested as for analysis of PARP cleavage, but resuspended
in PIPES buffer. Extracts containing 50 µ g protein were combined
with a 1.25 ml assay buffer and DEVD.afc enzyme substrate (final
concentration 2.5 mM). The samples were assayed for caspase-3
activity using a luminescent spectrophotometer (Perkin Elmer LS
50B, Beaconsfield, UK). Results were calculated as units of
enzyme activity (pmol mg–1 protein min–1) using UV WinLab soft-
ware. 
Measurement of AP-1 transactivation 
The TPA response element reporter construct (TRE-pGL2), kindly
provided by Professor P. Parker (ICRF, London, UK), contained 3
tandem TRE sites upstream of a luciferase coding region, and was
transfected into cells using electroporation or FuGene. In the case
of electroporation, 8 × 107 cells were transfected with the TRE-
pGL2 reporter construct (2.5 pmol), together with a control
expression vector containing the β -galactosidase gene driven by
the human cytomegalovirus immediate early gene promoter,
pCMVβ (0.075 pmol). Cells were allowed to recover in medium
containing 10% FCS for 5 h, after which they were serum starved
for 24 h. Transfections with FuGene involved serum starvation of
cells (3 × 106 per 35 mm well) for 24 h, followed by incubation for
24 h with FuGene, TRE-pGL2 construct (0.29 pmol) and pCMVβ
(0.23 pmol). After transfection by either method, cells were
exposed to genistein (1, 10 or 50 µ M) for 1 h, prior to incubation
with TPA (0.2 µ M) for 4 h. Luciferase and β -galactosidase
enzyme activites were determined using Promega assay kits and a
Wallac Microbeta 1450 plate reader, or Labsystems iEMS plate
reader, respectively. The expression of β -galactosidase was used to
control for transfection efficiency by normalizing all results to
expression of this gene. 
Western blot analysis of phosphorylated ERKs and
fos/jun proteins and measurement of JNK activity 
Cells were seeded at 2–4 × 106 per well (35 mm), allowed to
adhere, serum starved for 24 h and treated with genistein (50 µ M)
for 30 min prior to inclusion in the medium for 2 h of either TPA
(0.2 µ M) in the case of analysis of c-fos levels and ERK phospho-
rylation, or anisomycin (100 nM) for analysis of c-jun and JNK
activity. Proteins were extracted either from whole cells for thedetermination of ERK phosphorylation and JNK activity or from
isolated nuclei for analysis of c-fos and c-jun levels. For Western
analysis, proteins were electrophoretically separated on a 10%
polyacrylamide gel and transferred to nitrocellulose (Hybond,
Amersham Life Science Ltd) using a wet blotting system. For
analysis of ERKs, membranes were blocked in 5% bovine serum
albumin, and for analysis of c-fos and c-jun, in 10% non-fat milk
and TBS-T at 4˚C for 24 h. Membranes were then incubated with
antibodies specific for either pERK (1:2000 dilution) for 90 min or
c-fos or c-jun (1:2000 dilution) for 2 h. Membranes were washed
with TBS-T, incubated with a secondary antibody conjugated with
horseradish peroxidase, and the signal was detected using the ECL
detection system. Scanning and densitometry were performed
using a Molecular Dynamics Densitometer and quantified by
Image Quant Analysis software. 
After treatment with anisomycin and/or genistein, protein
extracts of ZR-75.1 and MCF-7 cells were subjected to a JNK
kinase assay as described by Croisy–Delcey et al (1997).
Phosphorylation of GST-c-jun was analysed by SDS PAGE. Gels
were transferred onto blotting paper, dried at 65˚C for 1 h and
visualized by autoradiography after incubation for 6 h at –80˚C.
Scanning and densitometry were performed using a Molecular
Dynamics PhosphorImager and quantified by Image Quant
Analysis software. 
Statistical analysis 
Statistical significance was assessed using the ANOVA General
Linear Model (Afifi and Azen, 1979) followed by Fisher’s least
significant difference posthoc test (Snedecor and Cochran, 1980)
or one-way ANOVA followed by Tukey’s posthoc test. 
RESULTS 
Effect of genistein on cell growth and survival and cell
cycle distribution 
Human-derived breast cells were incubated with genistein at 1 µ M
or 10 µ M. At the low concentration, genistein accelerated the
growth of MCF-7 cells, increasing cell numbers by 40% over
controls. This mitogenic effect of genistein was not seen in any of
the other 5 cell types (Figure 1). At the higher concentration,
genistein inhibited the growth of MCF-7, MDA-MB 468, ZR 75.1
and MDA-MB 231 cells, but not of HBL 100 and T47-D cells,
when cells were cultured with medium containing 10% FCS
(Figure 1A). In order to determine whether constituents of the
medium influence cell growth modulation by genistein, its effect
on cell numbers was reinvestigated under conditions of low serum
concentration (2%). The effects of genistein on the growth of cells
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Figure 1 Effect of genistein 1 µ M (open bars) and 10 µ M (closed bars) on the growth of breast cells cultured for 96 h in medium with 10% FCS (A) or 2% FCS
(B). Results, which are presented as percentage of cells in control cultures, are the mean ± SEM of 3 independent determinations, each conducted in duplicate.
Asterisks indicate that values are significantly different from controls (P < 0.05, two-way ANOVA followed by Fisher’s least significant difference posthoc test).
For details of culture conditions, see Materials and methods cultured under these conditions differed from that observed under
normal culture conditions (10% FCS), in that genistein (10 µ M)
inhibited cell numbers significantly also in HBL 100 and T47-D
cells and was a more potent inhibitor of the growth of MDA-MB
468, ZR-75.1 and MDA-MB-231 cells (Figure 1B). 
The hypothesis that genistein-induced growth arrest was related
to induction of apoptosis was tested. Consistent with previous
reports (Li et al, 1999; Balabhadrapathruni et al, 2000), genis-
tein induced apoptosis in MDA-MB 468 cells grown in media
with either 10% or 2% FCS, as borne out by measurement of
annexin staining, PARP cleavage and caspase-3 activity after
incubation for 96 h. The percentage of apoptotic cells as
adjudged by annexin staining in cells incubated in medium with
10% FCS and genistein (10 µ M) rose from 5% in controls to
19.5%. Analysis of PARP protein by Western blot showed a
decrease in PARP protein band intensity of 38% in cells exposed to
genistein, as compared to control cells, suggesting genistein-
induced PARP degradation in these cells. Furthermore, genistein
increased caspase-3 enzyme activity 5-fold over that in control
cells (results not shown). In the other 5 breast cell types, genistein
did not cause changes indicative of apoptosis, although it increased
the necrotic cell population slightly. 
The mitogenic effect of genistein (1 µ M) in MCF-7 cells was
not accompanied by any significant change in cell cycle distribu-
tion. However, genistein (10 µ M) blocked cell cycle progression in
the G2/M phase in 5 of the 6 cell types grown in 2% FCS (Table 1).
ZR 75.1 cells were insensitive towards the G2/M phase blockade
elicited by genistein, but unlike the other cells they accumulated
somewhat in G1. 
Effect of genistein on TPA-induced AP-1
transactivation, ERK phosphorylation and levels of 
c-fos and c-jun 
Cells were transfected with a TRE-pGL2 reporter construct, the
activity of which reflects AP-1 transactivation, as it contains 3
TRE sites upstream of a luciferase gene. TPA increased luciferase
activity 1.5- to 10-fold over control values in HBL 100, ZR-75.1,
MDA-MB 468 and T47-D, but failed to induce AP-1 activity in
MCF-7 and MDA-MB 231 cells. TPA was without effect in cells
into which the empty vector had been transfected. The effect of
genistein (1–50 µ M) on TPA-induced luciferase expression was
examined. Genistein reduced luciferase activity only in MDA-MB
468 and T47-D cells (results not shown), albeit the extent of reduc-
tion was variable and not significant, and it was observed only at
the highest genistein concentration. In all of these experiments
Fugene was used to transfect the reporter construct into cells. The
inhibitory activity of genistein was confirmed in experiments in
which the TRE-pGL2 reporter construct was transfected into
MDA-MB 468 cells using electroporation. In these cells the extent
of TPA-induced luciferase expression was similar to that observed
in cells transfected by Fugene, and genistein (50 µ M) decreased it
significantly by 75 ± 2% (mean ± SD; n = 3). Paradoxically, in ZR
75.1 cells genistein (50 µ M) augmented, rather than decreased,
TPA-induced luciferase expression, even though this elevation was
highly variable. In the absence of TPA, genistein did not augment
AP-1 activity. 
Changes in AP-1 activity can be mediated by alterations of
elements of the MAPK cascade via the ERKs. The effect of genis-
tein on TPA-induced ERK 1 and 2 phosphorylation was studied
using Western blot analysis. TPA induced ERK 1 and 2 phospho-
rylation in T47-D, ZR-75.1 (Figure 2A) and MCF-7 cells (result
not shown). Such induction was not reproducibly observed in HBL
100, MDA-MB 468 or MDA-MB 231 cells. Genistein (50 µ M)
significantly inhibited TPA-induced ERK phosphorylation in ZR-
75.1 and T47-D cells, by 70% and 47%, respectively (Figure 2A),
but not in MCF-7 cells (results not shown). 
To examine the mechanism by which genistein regulates AP-1
transactivation, its effects on levels of c-fos and c-jun, major
constituents of the AP-1 complex, were studied. Expression of
c-fos and c-jun was stimulated by incubation of cells with TPA
and anisomycin, respectively. Genistein (50 µ M) decreased c-fos
levels in MDA-MB 468 and T47-D cells by 77% and 73%, respec-
tively (Figure 2B). In contrast, genistein stimulated levels of c-jun
over those elicited by anisomycin 2.5 and 3-fold in MCF-7 and
ZR-75.1 cells, respectively (Figure 2C). Genistein on its own in the
absence of anisomycin did not affect c-jun levels (results not
shown). It was also devoid of any effect on induced c-fos or c-jun
levels in HBL 100 and MDA-MB 231 cells, on c-fos in MCF-7 and
ZR-75.1 cells or on c-jun in MDA-MB 468 and T47-D cells
Inhibition of breast cell growth by genistein 621
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Table 1 Effect of genistein (10 µ M) on cell cycle distribution of breast cells cultured in 2% FCS 
Cell type Treatment
Cell cycle distribution* 
G1 S G2/M 
HBL 100 Control 61.8 ± 3.1 13.8 ± 3.6 20.2 ± 3.1 
Genistein 34.4 ± 16.5† 13.7 ± 2.1 45.5 ± 13.8* 
MCF-7 Control 78.1 ± 7.7 9.6 ± 2.9 8.5 ± 3.1 
Genistein 79.2 ± 2.4 9.2 ± 2.4 22.0 ± 4.2* 
MDA-MB 468 Control 72.0 ± 6.0 11.1 ± 2.8 13.7 ± 6.1 
Genistein 62.2 ± 13.0 11.2 ± 2.8 43.3 ± 18.6* 
ZR-75.1 Control 77.9 ± 8.8 8.8 ± 4.9 9.9 ± 2.6 
Genistein 86.2 ± 5.3 4.8 ± 2.4 7.7 ± 2.3 
T47-D Control 76.7 ± 2.5 8.8 ± 1.4 11.5 ± 4.2 
Genistein 65.8 ± 10.5* 7.3 ± 1.4 20.9 ± 8.3* 
MDA-MB 231 Control 74.6 ± 2.9 6.3 ± 2.3 17.3 ± 1.7 
Genistein 63.3 ± 25.6* 9.2 ± 4.0 25.9 ± 6.0* 
*Results are presented as percentage values and are the mean ± SEM of four separate
experiments, each conducted in duplicate. †Significantly different from control cells (P < 0.05,
general linear model ANOVA, followed by Fisher’s least significant difference posthoc test). (results not shown). In order to assess the effect of genistein on
JNK activity in the 2 cell types in which genistein increased c-jun
protein levels, its effect on anisomycin-induced c-jun phosphoryl-
ation was studied. Anisomycin induced JNK phosphorylating
activity by a factor of 5.5 ± 1.2 over controls in ZR-75.1 cells, and
by 3.5 ± 0.7 in MCF-7 cells (n = 3). Genistein (50 µ M) reduced it
back to control levels in ZR-75.1 cells but not in MCF-7 cells
(results not shown). 
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Figure 2 Effect of genistein (50 µ M) on (A) TPA-induced ERK phosphorylation in T47D and ZR-75.1 cells, with a representative blot for ZR-75.1 cells,
(B) TPA-induced c-fos levels in T47-D and MDA-MB 468, with a representative blot for MDA-MB 468 cells, and (C) anisomycin-induced c-jun levels in MCF-7
and ZR-75.1 cells, with a representative blot for ZR-75.1 cells. Values were derived by laser densitometry from Western blot analyses. Genistein alone did not
affect c-jun levels. Results are presented as fold changes in band density compared to control incubates. Open bars represent values after treatment with TPA
(0.2 µ M) (A, B) or anisomycin (100 µ M) (C) only. Closed bars represent values after treatment with TPA (A, B) or anisomycin (C), plus genistein. Results are the
mean ± SEM of 3 independent experiments. Asterisks indicate that values are significantly different from those obtained in the presence of TPA or anisomycin
only (P < 0.05, two-way ANOVA followed by Fisher’s least significant difference posthoc test). For details of incubation and Western analysis see Materials and
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DISCUSSION 
The results presented earlier show that the growth of all 6 human
breast cell lines investigated in this study was affected by genistein
at 10 µ M, when cells were cultured in medium containing only 2%
serum. Nevertheless there were differences between cells in terms
of their sensitivity towards genistein. The enhancement of breast
cell growth by genistein (1 µ M), as seen in MCF-7 cells, is not a
generic feature of human breast cells. The observation that genis-
tein in the 10–6 M range promotes the growth of MCF-7 has raised
concern that physiologically achievable concentrations of genis-
tein might support, rather than counteract, the progression of
breast cancer in women with pre-diagnostic neoplastic changes
(Zava and Duwe, 1997; Fioravanti et al, 1998; Bail et al, 1998;
Hsieh et al, 1998). Such an effect would severely confound any
potential benefit of genistein consumption. Growth promotion has
been associated with the interaction of genistein with ER-α and -β
(Kuiper et al, 1997; 1998). A review of the relevant, partially
contradictory and confusing literature (Enmark et al, 1997;
Nakatani et al, 1999; Shao et al, 1998; Fioravanti et al, 1998;
Dotzlaw et al, 1996) and complementary unpublished observations
in this laboratory (Dampier, 2001) regarding levels of ER-α
protein and ER-β mRNA suggest tentatively that HBL-100, MDA-
MB 231 and MDA-MB 468 cells have ER-β , ZR-75.1 and T47-D
cells possess ER-α , and MCF-7 cells have both receptors. This
comparison renders the possibility unlikely that the growth promo-
tion caused by genistein specifically in MCF-7 cells is intrinsically
linked to expression of either ER-α or -β . 
The notion that divergent mechanisms mediate the growth-
arresting efficacy of genistein in the different breast cell lines is
supported by the following 4 pieces of evidence: 
1. The susceptibility of the cells towards growth inhibition by
genistein was differentially affected by the serum content of
the medium. 
2. Genistein caused apoptosis in MDA-MB 468 cells, but not in
MCF-7, ZR-75 or MDA 231 cells, which were similarly
susceptible to genistein-induced growth arrest as MDA-MB
468. 
3. Under culture conditions with low FCS (2%) genistein 
significantly arrested cells in the G2 phase of the cell cycle in
5 of the 6 cell lines, but not ZR-75.1, in which growth arrest
was accompanied by a slight increase in the G1 cell 
population. 
4. Cells differed considerably in their susceptibilities towards
inhibition by genistein of elements of TPA-induced cell
signalling: AP-1 activity was inhibited only in MDA-MB
468 and T47-D cells, ERK activation only in ZR 75.1 and
T47-D cells, and c-fos levels only in MDA-MB 468 and
T47-D cells. 
Some of these observations can be rationalized in terms of mecha-
nistic connectivity or complementarity. Table 2 summarizes some
of the effects of genistein on growth, apoptosis, cell cycle distribu-
tion, AP-1 activity, ERK phosphorylation, and c-fos and c-jun
protein levels in the cell lines studied. In ZR-75.1 cells genistein
appeared to increase, rather than decrease, tumour promoter-mediated
AP-1 activity. Compatible with this observation, genistein
increased c-jun protein levels in the presence of the jun activator
anisomycin. However this increase was accompanied by a
decrease in anisomycin-induced JNK activity. So, the functional
consequences of the contrasting changes elicited by genistein with
respect to c-jun protein on the one hand and JNK activity on the
other are difficult to predict. In T47-D cells, the decrease of ERK
phosphorylation is compatible with the attenuation of both c-fos
protein levels and AP-1 activity. This coincidence suggests that in
these cells genistein may inhibit growth by interfering with MAPK
signalling, which in turn abrogates AP-1 transcription via attenua-
tion of c-fos expression. In MDA-MB 468 cells, the observed
reduction by genistein of c-fos protein expression, compatible with
the effect of genistein on c-fos transcription reported previously
(Schultze-Mosgau et al, 1998), explains the amelioration of AP-1
activity. These events might contribute to the growth-inhibitory
and apoptosis-inducing effects of genistein in MDA-MB 468 cells.
Undoubtedly the concentrations of genistein that have been
reported here and by others to elicit growth arrest and cause
changes in signalling, are higher than the 3–4 µ M reported to be
achieved in the plasma of individuals who consume large amounts
of soya (Adlercreutz et al, 1995; Barnes and Peterson, 1995).
Nevertheless, as genistein and related isoflavanoid molecules have
recently been discussed as potential chemopreventive or
chemotherapeutic agents in their own right and not only as
Table 2 Effects of genistein on breast-derived cell types 
Cell type 
HBL 100 MCF-7 MDA 468 ZR-75 T47-D MDA 231 
Growth inhibition* –†‡ +++ –‡ +
Apoptosis* ––+ –––
G2/M arrest§ +++– ++
G1 arrest§ –––+ ––
AP-1 transactivation (+TPA only)¶ ↑ – ↑↑ ↑ –
AP-1 transactivation (+ TPA and genistein)** ––↓↑ ↓ –
c-fos levels (+TPA and genistein)** ––↓ – ↓ –
c-jun levels (+ anisomycin and genistein)** – ↑ – ↑ ––
ERK 1/2 phosphorylation (+TPA only)¶ – ↑ – ↑↑ –
ERK 1/2 phosphorylation (+ TPA and genistein)** –––↓↓ –
*Effect of genistein (10 µ M) in cells maintained in 10% FCS; †–: no effect, +: effect, ↑: upregulation, ↓ : downregulation; ‡Note that the
growth of HBL 100 and T47-D cells was inhibited by genistein when cells were cultured with 2% rather than 10% FCS; §Effect of
genistein(10 µ M) in cells maintained in 2% FCS; ¶Effect of TPA alone; **Effect of genistein (50 µ M) after stimulation by TPA or
anisomycin. For details see results and discussion. 624 K Dampier et al 
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constituents of the food matrix, it is conceivable that they could be
administered clinically at much higher doses than those associated
with dietary polyphenol consumption, thus potentially achieving
target tissue concentrations in the 10–5–10–4 M range. 
In conclusion, our findings suggest that whilst genistein at
higher concentrations consistently arrests the growth of breast
cells when they are cultured under low serum conditions, suscepti-
bility to growth promotion induced by genistein at low concentra-
tions is not a generic feature of cells derived from this tissue. The
results are consistent with the notion that induction of apoptosis,
G2 cell cycle arrest and inhibition of components of MAPK
signalling, c-fos protein expression and AP-1 transactivation may
contribute to the growth-inhibitory effect of genistein in some
breast cell types. None of these effects of genistein constitutes a
predominant mode of growth-arresting action as they do not occur
consistently in all breast cell lines. Therefore this study does not
suggest a unifying picture of the molecular events exerted by
genistein. Instead, the relative importance of the individual compo-
nents of the heterogeneous spectrum of mechanisms associated
with growth modulation by this isoflavone is probably breast cell
type specific. 
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